IL6 and diabetes mellitus: Targeting the overexpression of IL-6 effects with a monoclonal antibody against IL-6 receptor or using Janus Kinase inhibitors may be particularly helpful for treatment of COVID-19 pneumonia in diabetes in the future (51).